Screening for acute i kr block is insufficient to detect torsades de pointes liability: Role of late sodium current

Circulation

Volumn 130, Issue 3, 2014, Pages 224-234

  Yang, Tao ^a   Chun, Young Wook ^a   Stroud, Dina M ^a   Mosley, Jonathan D ^a   Knollmann, Bjorn C ^a   Hong, Charles ^a   Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

human; KCNH2 potassium channel; Nav1.5 voltage gated sodium channel; phosphatidylinositol 3 kinases; potassium channels

Indexed keywords

DOFETILIDE; MOXIFLOXACIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; POTASSIUM CHANNEL; PROTEIN KINASE B; 4 AMINOPYRIDINE; PHENETHYLAMINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM CHANNEL BLOCKING AGENT; SCN5A PROTEIN, MOUSE; SODIUM CHANNEL NAV1.5; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARRHYTHMOGENESIS; ARTICLE; CHO CELL LINE; DRUG EFFECT; DRUG EXPOSURE; GENETIC TRANSFECTION; HEART MUSCLE CELL; MOUSE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QT PROLONGATION; SCREENING; TORSADE DES POINTES; ACTION POTENTIAL; ANIMAL; ANIMAL MODEL; C57BL MOUSE; CELL CULTURE; CRICETULUS; DRUG SCREENING; FEMALE; GENETICS; HAMSTER; HEK293 CELL LINE; HUMAN; KCNH2 POTASSIUM CHANNEL, HUMAN; METABOLISM; METHODOLOGY; PATCH CLAMP TECHNIQUE; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION;

KCNH2 POTASSIUM CHANNEL, HUMAN; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; PHOSPHATIDYLINOSITOL 3-KINASES; POTASSIUM CHANNELS;

4-AMINOPYRIDINE; ACTION POTENTIALS; ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; DRUG EVALUATION, PRECLINICAL; FEMALE; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MYOCYTES, CARDIAC; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; PATCH-CLAMP TECHNIQUES; PHENETHYLAMINES; PHOSPHATIDYLINOSITOL 3-KINASES; POTASSIUM CHANNEL BLOCKERS; PROTO-ONCOGENE PROTEINS C-AKT; RISK FACTORS; SIGNAL TRANSDUCTION; SULFONAMIDES; TORSADES DE POINTES; TRANSFECTION;

EID: 84904573224     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.007765     Document Type: Article

References (49)

1. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, Cantilena LR; Independent Academic Task Force. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol. 2004;15:475-495.
2. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022.
3. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, Wagner JA. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008;84:475-480.
4. Dale KM, Lertsburapa K, Kluger J, White CM. Moxifloxacin and torsade de pointes. Ann Pharmacother. 2007;41:336-340.
5. Kim TD, le Coutre P, Schwarz M, Grille P, Levitin M, Fateh-Moghadam S, Giles FJ, Dörken B, Haverkamp W, Köhncke C. Clinical cardiac safety profile of nilotinib. Haematologica. 2012;97:883-889.
6. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosomepositive ALL. N Engl J Med. 2006;354:2542-2551.
7. Lu Z, Wu CY, Jiang YP, Ballou LM, Clausen C, Cohen IS, Lin RZ. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med. 2012;4:131ra50.
8. Mounsey JP, DiMarco JP. Dofetilide. Circulation. 2000;102:2665-2670.
9. Wang L, Feng ZP, Kondo CS, Sheldon RS, Duff HJ. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res. 1996;79:79-85.
10. Liu K, Yang T, Viswanathan PC, Roden DM. New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation. 2005;112:3239-3246.
11. Lowe JS, Stroud DM, Yang T, Hall L, Atack TC, Roden DM. Increased late sodium current contributes to long QT-related arrhythmia susceptibility in female mice. Cardiovasc Res. 2012;95:300-307.
12. Yang T, Atack TC, Stroud DM, Zhang W, Hall L, Roden DM. Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res. 2012;111:322-332.
13. Watanabe H, Yang T, Stroud DM, Lowe JS, Harris L, Atack TC, Wang DW, Hipkens SB, Leake B, Hall L, Kupershmidt S, Chopra N, Magnuson MA, Tanabe N, Knollmann BC, George AL Jr, Roden DM. Striking in vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro. Circulation. 2011;124:1001-1011.
14. Yu J, Chau KF, Vodyanik MA, Jiang J, Jiang Y. Efficient feeder-free episomal reprogramming with small molecules. PLoS One. 2011;6:e17557.
15. Zhang J, Klos M, Wilson GF, Herman AM, Lian X, Raval KK, Barron MR, Hou L, Soerens AG, Yu J, Palecek SP, Lyons GE, Thomson JA, Herron TJ, Jalife J, Kamp TJ. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res. 2012;111:1125-1136.
16. Matsushita Y, Ohya S, Suzuki Y, Itoda H, Kimura T, Yamamura H, Imaizumi Y. Inhibition of Kv1.3 potassium current by phosphoinositides and stromal-derived factor-1alpha in Jurkat T cells. Am J Physiol Cell Physiol. 2009;296:C1079-C1085.
17. Mantegazza M, Franceschetti S, Avanzini G. Anemone toxin (ATX II)-induced increase in persistent sodium current: effects on the firing properties of rat neocortical pyramidal neurones. J Physiol. 1998;507(pt 1):105-116.
18. Macianskiene R, Bito V, Raeymaekers L, Brandts B, Sipido KR, Mubagwa K. Action potential changes associated with a slowed inactivation of cardiac voltage-gated sodium channels by KB130015. Br J Pharmacol. 2003;139:1469-1479.
19. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res. 1999;84:989-998.
20. Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM. MICE models: superior to the HERG model in predicting torsade de pointes. Sci Rep. 2013;3:2100.
21. Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC, Shyjka LM, Lacerda AE, Brown AM. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods. 2004;50:93-101.
22. Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation. 1995;91:3010-3016.
23. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006;316:1098-1106.
24. Drolet B, Vincent F, Rail J, Chahine M, Deschênes D, Nadeau S, Khalifa M, Hamelin BA, Turgeon J. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther. 1999;288:1261-1268.
25. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158:1774-1782.
26. Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, Diecke S, Sallam K, Knowles JW, Wang PJ, Nguyen PK, Bers DM, Robbins RC, Wu JC. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013;127:1677-1691.
27. Jonsson MK, Vos MA, Mirams GR, Duker G, Sartipy P, de Boer TP, van Veen TA. Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG. J Mol Cell Cardiol. 2012;52:998-1008.
28. Song W, Xiao Y, Chen H, Ashpole NM, Piekarz AD, Ma P, Hudmon A, Cummins TR, Shou W. The human Nav1.5 F1486 deletion associated with long QT syndrome leads to impaired sodium channel inactivation and reduced lidocaine sensitivity. J Physiol. 2012;590(pt 20):5123-5139.
29. Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov. 2003;2:439-447.
30. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA. 2000;97:12329-12333.
31. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ. Dofetilide in patients with congestive heart failure and left ventricular dysfunction: Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341: 857-865.
32. Wiesfeld AC, Crijns HJ, Bergstrand RH, Almgren O, Hillege HL, Lie KI. Torsades de pointes with Almokalant, a new class III antiarrhythmic drug. Am Heart J. 1993;126:1008-1011.
33. Shah R. Drugs, QTc Interval prolongation and final ICH E14 guideline. Drug-Safety. 2005;28:1009-1028.
34. Choy AMJ, Darbar D, Dell'Orto S, Roden DM. Increased sensitivity to QT prolonging drug therapy immediately after cardioversion to sinus rhythm. J Am Coll Cardiol. 1999;34:396-401.
35. Kaab S, Duc J, Ashen D, Näbauer M, Beuckelmann DJ, Dixon J, McKinnon D, Tomaselli GF. Quantitative analysis of K channel mRNA expression in normal and failing human ventricle reveals the molecular identity of Ito1. Circulation. 1996;94:I-592.
36. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med. 2006;259:59-69.
37. Roden DM. Repolarization reserve: a moving target. Circulation. 2008;118:981-982.
38. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000;19:2537-2548.
39. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol. 2002;22:2799-2809.
40. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, Izumo S. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA. 2003;100:12355-12360.
41. Chaanine AH, Hajjar RJ. AKT signalling in the failing heart. Eur J Heart Fail. 2011;13:825-829.
42. Pretorius L, Du XJ, Woodcock EA, Kiriazis H, Lin RC, Marasco S, Medcalf RL, Ming Z, Head GA, Tan JW, Cemerlang N, Sadoshima J, Shioi T, Izumo S, Lukoshkova EV, Dart AM, Jennings GL, McMullen JR. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol. 2009;175:998-1009.
43. Shryock JC, Song Y, Rajamani S, Antzelevitch C, Belardinelli L. The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. Cardiovasc Res. 2013;99:600-611.
44. Hoffmann P, Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods. 2006;53:87-105.
45. Lu HR, Vlaminckx E, Hermans AN, Rohrbacher J, Van Ammel K, Towart R, Pugsley M, Gallacher DJ. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br J Pharmacol. 2008;154:1427-1438.
46. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, Wible BA, Brown AM. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol. 2004;66:33-44.
47. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, Reynolds W, Rampe D. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther. 2005;312:316-323.
48. Kuryshev YA, Wang L, Wible BA, Wan X, Ficker E. Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents. Mol Pharmacol. 2006;69:1216-1225.
49. Lacerda AE, Kuryshev YA, Chen Y, Renganathan M, Eng H, Danthi SJ, Kramer JW, Yang T, Brown AM. Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther. 2008;324:427-433.